DCVax-L: Phase III ongoing

Northwest Biotherapeutics said a DSMB recommended continuation of a double-blind, international Phase III trial evaluating DCVax-L in 312 GBM patients based on a review of safety data. Patients with newly diagnosed GBM indicated for surgery are receiving 2 intradermal injections of DCVax-L or placebo on days 0, 10 and 20 and at weeks 8, 16, 32, 48, 72, 96 and 120. The trial was originally designated a Phase II trial but was amended to include another cohort and increase enrollment (see BioCentury, May 28, 2012). ...